New drug combo aims to slow lung damage in rare muscle disease
Disease control
Completed
This study tested whether adding nintedanib (OFEV) to standard immunosuppressant therapy can improve symptoms in people with myositis-associated interstitial lung disease, a condition where lung tissue becomes scarred and stiff. 49 adults in the U.S. participated, receiving eithe…
Phase: PHASE4 • Sponsor: Rohit Aggarwal, MD • Aim: Disease control
Last updated Jun 27, 2026 09:07 UTC